Filing Flows › Comparisons › CYTK vs NUVB
Cytokinetics vs Nuvation Bio: CYTK and NUVB compared
Cytokinetics is the larger company: $47.6M of revenue in its latest quarter (Q3 2026) against $45.0M for Nuvation Bio (Q3 2026). Cytokinetics is growing faster (25× against +243% a year earlier). Nuvation Bio is more profitable, with an operating margin of -93.9% against -351.3%.
Where the money goes: CYTK and NUVB
Cytokinetics (CYTK) · Q3 2026
Cytokinetics, Q3 2026: revenue $47.6M (25× year over year), operating margin -351.3%, net loss $190M, operating cash flow −$124M. The chart follows the revenue to costs, profit and cash.
Nuvation Bio (NUVB) · Q3 2026
Nuvation Bio, Q3 2026: revenue $45.0M (+243% year over year), operating margin -93.9%, net loss $41.9M, operating cash flow −$38.6M. The chart follows the revenue to costs, profit and cash.
| Cytokinetics (CYTK) | Nuvation Bio (NUVB) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $47.6M | $45.0M |
| Revenue growth, Y/Y | 25× | +243% |
| Operating margin | -351.3% | -93.9% |
| Net earnings | −$190M | −$41.9M |
| Net margin | -399.7% | -93.2% |
| Operating cash flow | −$124M | −$38.6M |
| Market value | $8.4B | $1.5B |
| Analysts’ mean target | $107.22 | $13.00 |
Where the revenue comes from
Cytokinetics
- Net Product Revenue: $44.5M (94%)
- Collaboration Revenues: $3.0M (6%)
Nuvation Bio
- Product Revenue: $27.5M (61%)
- License: $17.5M (39%)
Questions
Which is bigger, Cytokinetics or Nuvation Bio?
Cytokinetics is the larger company: $47.6M of revenue in its latest quarter (Q3 2026) against $45.0M for Nuvation Bio (Q3 2026).
Is Cytokinetics or Nuvation Bio growing faster?
Cytokinetics is growing faster (25× against +243% a year earlier).
Which is more profitable, Cytokinetics or Nuvation Bio?
Nuvation Bio is more profitable, with an operating margin of -93.9% against -351.3%.
More: Cytokinetics earnings · how Cytokinetics makes money · Nuvation Bio earnings · how Nuvation Bio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.